The association of 5 alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population

Basit Öğe Kaydı
dc.authorid0000-0002-7220-0066
dc.authorid0000-0003-0157-464X
dc.contributor.authorÖnen, İlke Hacer
dc.contributor.authorEkmekçi, Abdullah
dc.contributor.authorEroğlu, Muzaffer
dc.contributor.authorPolat, Fazlı
dc.contributor.authorBiri, Hasan
dc.date.accessioned2021-06-23T19:20:30Z
dc.date.available2021-06-23T19:20:30Z
dc.date.issued2007
dc.departmentBAİBÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.departmentBAİBÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.description19th European Workshop on Drug Metabolism -- OCT 03-08, 2004 -- Antalya, TURKEYen_US
dc.description.abstractTo date, research has led to the invention of multiple genes and their single nucleotide polymorphisms (SNPs) and environmental factors that influence the prostate cancer (PCa) pathogenesis. Therefore, the genes involved in these pathways are candidates for PCa predisposition. It is thought that polymorphisms of 5α-reductase II (SRD5A2) and 17 hydroxylase (CYP17) genes are likely to increase susceptibility. The aim of this study was to investigate the risk association of SRD5A2 and CYP17 gene polymorphisms in the development and progression of PCa in the Turkish population. In this study, 100 PCa patients and 105 healthy controls were studied. SRD5A2 and CYP17 gene polymorphisms were determined by real-time PCR and polymerase chain reaction-restriction length polymorphisms (PCR-RFLP) techniques. First, the AT and TT genotypes of SRD5A2 gene at codon 49 were not observed. Second, there was no significant association between the polymorphisms at codon 89 and the risk of PCa. Third, in the CYP17 gene, the A1A1 genotype is more common (46%) in cases than controls (32.4%). The odds ratios (ORs) of the A1A1 genotype was found at 1.69 (95% confidence interval [CI], 0.77–3.74) compare with the A2A2 genotype. Genotyping results of the SRD5A2 and CYP17 genes were also analyzed in relation to prostate-specific antigen (PSA) levels, Gleason score (GS), and tumor stage, but no statistically significant difference was observed (P > 0.05). Finally, we conclude that there was no evidence of an association between CYP17 (P = 0.134) and SRD5A2 (P = 0.784) polymorphism and PCa risk in the Turkish population.en_US
dc.identifier.doi10.1089/dna.2006.0534
dc.identifier.endpage107en_US
dc.identifier.issn1044-5498
dc.identifier.issn1557-7430
dc.identifier.issue2en_US
dc.identifier.pmid17328668en_US
dc.identifier.scopus2-s2.0-33847690738en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage100en_US
dc.identifier.urihttps://doi.org/10.1089/dna.2006.0534
dc.identifier.urihttps://hdl.handle.net/20.500.12491/6123
dc.identifier.volume26en_US
dc.identifier.wosWOS:000244604700004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorEroğlu, Muzaffer
dc.language.isoenen_US
dc.publisherMary Ann Liebert Inc.en_US
dc.relation.ispartofDna And Cell Biologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectProstate Canceren_US
dc.titleThe association of 5 alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish populationen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Koleksiyonu